The use of G-CSF and GM-CSF in bone marrow transplantation
Donald G. Vidt, MD
Alan Bakst, PharmD
Brian J. Bolwell, MDAddress reprint requests to B.J.B., Department of Hematology and Oncology, T33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.
Bone marrow transplantation is accepted as potentially curative therapy for a variety of patients with hematologic malignancies and other disorders. The most important causes of morbidity are infections and bleeding secondary to prolonged cytopenias. Granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) have been shown to potentially enhance bone marrow engraftment which has translated into reduced morbidity and mortality. Additionally, growth factors such as G-CSF and GM-CSF may increase numbers of circulating peripheral progenitor cells to serve as the source of “marrow” for transplantation. This review summarizes the current available data using G-CSF and GM-CSF in bone marrow transplantation and discusses potential areas of study with additional cytokines.